MedTrace Logo

Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients

NCT03939780 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-02-11

No results posted yet for this study

Summary

The primary objective of this study is to identify a new radioligand for imaging of tauopathy in Alzheimer's disease through direct comparisons of two potential candidates, \[18F\]RO-948 (formerly known as \[18F\]6958948) and \[18F\]MK-6240, and demonstration of the candidates' absence of off-target binding.

Conditions

  • Healthy
  • Alzheimer Disease

Interventions

DIAGNOSTIC_TEST

[F18]RO-948

Single radiotracer IV injection with subsequent emission scan

DIAGNOSTIC_TEST

[F18]MK-6240

Single radiotracer IV injection with subsequent emission scan

DIAGNOSTIC_TEST

[F18]AV1451

Single radiotracer IV injection with subsequent emission scan

Sponsors & Collaborators

Principal Investigators

  • Dean Wong, MD/PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2023-04-30
Completion
2023-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03939780 on ClinicalTrials.gov